Skip to main content

Xylocaine with Epinephrine Dental Cartridges Disease Interactions

There are 11 disease interactions with Xylocaine with Epinephrine Dental Cartridges (epinephrine / lidocaine).

Major

Antiarrhythmics (applies to Xylocaine with Epinephrine Dental Cartridges) cardiovascular dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Congestive Heart Failure, Hypotension

Antiarrhythmic agents can induce severe hypotension (particularly with IV administration) or induce or worsen congestive heart failure (CHF). Patients with primary cardiomyopathy or inadequately compensated CHF are at increased risk. Antiarrhythmic agents should be administered cautiously and dosage and/or frequency of administration modified in patients with hypotension or adequately compensated CHF. Alternative therapy should be considered unless these conditions are secondary to cardiac arrhythmia.

References

  1. Halkin H, Meffin P, Melmon KL, Rowland M (1975) "Influence of congestive heart failure on blood levels of lidocaine and its active monodeethylated metabolite." Clin Pharmacol Ther, 17, p. 669-76
  2. Crouthamel WG (1975) "The effect of congestive heart failure on quinidine pharmacokinetics." Am Heart J, 90, p. 335-9
  3. Ravid S, Podrid PJ, Lampert S, Lown B (1989) "Congestive heart failure induced by six of the newer antiarrhythmic drugs." J Am Coll Cardiol, 14, p. 1326-30
  4. Swiryn S, Kim SS (1983) "Quinidine-induced syncope." Arch Intern Med, 143, p. 314-6
  5. Gottlieb SS, Packer M (1989) "Deleterious hemodynamic effects of lidocaine in severe congestive heart failure." Am Heart J, 118, p. 611-2
  6. Ochs HR, Grube E, Greenblatt DJ, Arendt R (1981) "Intravenous quinidine in congestive cardiomyopathy." Eur J Clin Pharmacol, 19, p. 173-6
  7. Prescott LF, Adjepon-Yamoah KK, Talbot RG (1976) "Impaired lignocaine metabolism in patients with myocardial infarction and cardiac failure." Br Med J, 1, p. 939-41
  8. (2002) "Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories
  9. (2002) "Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals
  10. "Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories
  11. "Product Information. Quiniglute (quinidine)." Berlex, Richmond, CA.
  12. (2001) "Product Information. Adenocard (adenosine)." Fujisawa
  13. (2001) "Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim
  14. Thomson P, Melmon K, Richardson J, Cohn K Steinbrunn W, Cudihee R, Rowland M (1973) "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans." Ann Intern Med, 78, p. 499-508
  15. Singh SN, Fletcher RD, Fisher SG, et al. (1995) "Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia." N Engl J Med, 333, p. 77-82
  16. (2022) "Product Information. Cordarone (amiodarone)." Apothecon Inc
  17. (2001) "Product Information. Corvert (ibutilide)." Pharmacia and Upjohn
View all 17 references
Major

Lidocaine (applies to Xylocaine with Epinephrine Dental Cartridges) hepatic dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Liver Disease

Lidocaine is rapidly and extensively metabolized by the liver. Less than 10% is eliminated unchanged in the urine. Several inactive and two active forms (MEGX and GX) have been identified. MEGX and GX exhibit antiarrhythmic and convulsant properties. GX accumulates during prolonged intravenous lidocaine infusion. The pharmacokinetic disposition of lidocaine is altered by changes in hepatic function, including hepatic blood flow. Therapy with lidocaine should be administered cautiously and dosing modifications for repeated or loading and maintenance doses may be necessary. Clinical monitoring of cardiac (continuous ECG) is required and serum metabolite concentrations and monitoring hepatic function are recommended.

References

  1. Williams RL, Blaschke TF, Meffin PJ, et al. (1976) "Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: lidocaine and indocyanine green." Clin Pharmacol Ther, 20, p. 290-9
  2. Huet P-M, LeLorier J (1980) "Effects of smoking and chronic hepatitis B on lidocaine and indocyanine green kinetics." Clin Pharmacol Ther, 28, p. 208-15
  3. Bauer LA, Brown T, Gibaldi M, et al. (1982) "Influence of long-term infusions on lidocaine kinetics." Clin Pharmacol Ther, 31, p. 433-7
  4. Barry M, Keeling PW, Weir D, Feely J (1990) "Severity of cirrhosis and the relationship of a1-acid glycoprotein concentration to plasma protein binding of lidocaine." Clin Pharmacol Ther, 47, p. 366-70
  5. Thomson AH, Elliott HL, Kelman AW, et al. (1987) "The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects." J Pharmacokinet Biopharm, 15, p. 101-15
  6. Forrest JA, Finlayson ND, Adjepon-Yamoah KK, Prescott LF (1977) "Antipyrine, paracetamol, and lignocaine elimination in chronic liver disease." Br Med J, 1, p. 1384-7
  7. Colli A, Buccino G, Cocciolo M, et al. (1988) "Disposition of a flow-limited drug (lidocaine) and a metabolic capacity-limited drug (theophylline) in liver cirrhosis." Clin Pharmacol Ther, 44, p. 642-9
  8. Villeneuve JP, Thibeault MJ, Ampelas M, et al. (1987) "Drug disposition in patients with HBsAg-positive chronic liver disease." Dig Dis Sci, 32, p. 710-4
  9. Huet PM, Villeneuve JP (1983) "Determinants of drug disposition in patients with cirrhosis." Hepatology, 3, p. 913-8
  10. (2002) "Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals
  11. Huang YS, Lee SD, Deng JF, Wu JC, Lu RH, Lin YF, Wang YJ, Lo KJ (1993) "Measuring lidocaine metabolite - monoethylglycinexylidide as a quantitative index of hepatic function in adults with chronic hepatitis and cirrhosis." J Hepatol, 19, p. 140-7
  12. Thomson P, Melmon K, Richardson J, Cohn K Steinbrunn W, Cudihee R, Rowland M (1973) "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans." Ann Intern Med, 78, p. 499-508
  13. Shiffman ML, Luketic VA, Sanyal AJ, Duckworth PF, Purdum PP, Contos MJ, Mills AS, Edinboro LE, Poklis A (1994) "Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis." Hepatology, 19, p. 933-40
View all 13 references
Major

Lidocaine (applies to Xylocaine with Epinephrine Dental Cartridges) renal dysfunction

Major Potential Hazard, High plausibility.

Lidocaine is primarily eliminated by the kidney. Less than 10% is eliminated unchanged in the urine. Two active metabolites (MEGX and GX) have been identified that exhibit antiarrhythmic and convulsant properties. GX accumulates during prolonged intravenous lidocaine infusion. Serum concentrations of lidocaine and the active metabolites are increased and the half-life prolonged in patients with renal impairment. Therapy with lidocaine should be administered cautiously and dosing modified for repeated or maintenance doses in patients with compromised renal function. Clinical monitoring of cardiac function (continual ECG) is required and serum metabolite concentrations and monitoring renal function are recommended.

References

  1. Eriksson E, Granberg P-O, Ortengren B (1966) "Study of renal excretion of prilocaine and lidocaine." Acta Chem Scand, 358, p. 55-69
  2. Thomson PD, Rowland M, Melmon KL (1971) "The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man." Am Heart J, 82, p. 417-21
  3. Collinsworth KA, Strong JM, Atkinson AJ Jr, et al. (1975) "Pharmacokinetics and metabolism of lidocaine in patients with renal failure." Clin Pharmacol Ther, 18, p. 59-64
  4. Jacobi J, McGory RW, McCoy H, Matzke GR (1983) "Hemodialysis clearance of total and unbound lidocaine." Clin Pharm, 2, p. 54-7
  5. Vaziri ND, Saiki JK, Hughes W (1979) "Clearance of lidocaine by hemodialysis." South Med J, 72, p. 1567-8
  6. (2002) "Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals
  7. Grossman S, Davis D, Kitchell B, Shand D, Routledge P (1982) "Diazepam and lidocaine plasma protein binding in renal disease." Clin Pharmacol Ther, 31, p. 350-7
  8. Thomson P, Melmon K, Richardson J, Cohn K Steinbrunn W, Cudihee R, Rowland M (1973) "Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans." Ann Intern Med, 78, p. 499-508
View all 8 references
Major

Lidocaine (applies to Xylocaine with Epinephrine Dental Cartridges) seizures

Major Potential Hazard, High plausibility.

Seizures have occurred during lidocaine therapy and have been associated with the rapid administration of a large intravenous doses or accumulation of active metabolites with maintenance therapy. Therapy with lidocaine should be administered cautiously to patients with or predisposed to seizure disorders. Clinical monitoring of cardiac (continuous ECG) is required, and serum metabolite concentrations are recommended.

References

  1. Crampton RS, Oriscello RG (1968) "Petit and grand mal convulsions during lidocaine hydrochloride treatment of ventricular tachycardia." JAMA, 204, p. 109-12
  2. Sundaram MB (1987) "Seizures after intraurethral instillation of lidocaine." Can Med Assoc J, 137, p. 219-20
  3. Pelter MA, Vollmer TA, Blum RL (1989) "Seizure-like reaction associated with subcutaneous lidocaine injection ." Clin Pharm, 8, p. 767-8
  4. (2002) "Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals
  5. Fortuna A, Fortuna AO (1993) "Convulsion during lignocaine infiltration." Anaesth Intensive Care, 21, p. 483
  6. Ryan CA, Robertson M, Coe JY (1993) "Seizures due to lidocaine toxicity in a child during cardiac catheterization." Pediatr Cardiol, 14, p. 116-8
  7. Wu FL, Razzaghi A, Souney PF (1993) "Seizure after lidocaine for bronchoscopy: case report and review of the use of lidocaine in airway anesthesia." Pharmacotherapy, 13, p. 72-8
View all 7 references
Major

Lidocaine (applies to Xylocaine with Epinephrine Dental Cartridges) sinus/AV node dysfunction

Major Potential Hazard, High plausibility. Applicable conditions: Heart Block

The use of lidocaine is contraindicated in patients with Stokes-Adam syndrome, Wolff-Parkinson White syndrome, or second- or third-degree AV block in the absence of a functional artificial pacemaker, or congenital QT prolongation.

References

  1. Keidar S, Grenadier E, Palant A (1982) "Sinoatrial arrest due to lidocaine injection in sick sinus syndrome during amiodarone administration." Am Heart J, 104, p. 1384-5
  2. Tagliente TM, Jayagopal S (1989) "Transient left bundle branch block following lidocaine." Anesth Analg, 69, p. 545-7
  3. Hilleman DE, Mohiuddin SM, Destache CJ (1985) "Lidocaine-induced second-degree mobitz type II heart block." Drug Intell Clin Pharm, 19, p. 669-73
  4. (2002) "Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals
View all 4 references
Major

Sympathomimetics (applies to Xylocaine with Epinephrine Dental Cartridges) cardiovascular disease

Major Potential Hazard, High plausibility. Applicable conditions: Hyperthyroidism, Pheochromocytoma

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

References

  1. Humberstone PM (1969) "Hypertension from cold remedies." Br Med J, 1, p. 846
  2. Mariani PJ (1986) "Pseudoephedrine-induced hypertensive emergency: treatment with labetalol." Am J Emerg Med, 4, p. 141-2
  3. Rosen RA (1981) "Angina associated with pseudoephedrine ." Ann Emerg Med, 10, p. 230-1
  4. Wiener I, Tilkian AG, Palazzolo M (1990) "Coronary artery spasm and myocardial infarction in a patient with normal coronary arteries: temporal relationship to pseudoephedrine ingestion." Cathet Cardiovasc Diagn, 20, p. 51-3
  5. Gordon RD, Ballantine DM, Bachmann AW (1992) "Effects of repeated doses of pseudoephedrine on blood pressure and plasma catecholamines in normal subjects and in patients with phaeochromocytoma." Clin Exp Pharmacol Physiol, 19, p. 287-90
  6. Loizou LA, Hamilton JG, Tsementzis SA (1982) "Intracranial haemorrhage in association with pseudoephedrine overdose." J Neurol Neurosurg Psychiatry, 45, p. 471-2
  7. Dickerson J, Perrier D, Mayersohn M, Bressler R (1978) "Dose tolerance and pharmacokinetic studies of L (+) pseudoephedrine capsules in man." Eur J Clin Pharmacol, 14, p. 253-9
  8. Wooten MR, Khangure MS, Murphy MJ (1983) "Intracerebral hemorrhage and vasculitis related to ephedrine abuse." Ann Neurol, 13, p. 337-40
  9. To LB, Sangster JF, Rampling D, Cammens I (1980) "Ephedrine-induced cardiomyopathy." Med J Aust, 2, p. 35-6
  10. Bruno A, Nolte KB, Chapin J (1993) "Stroke associated with ephedrine use." Neurology, 43, p. 1313-6
  11. Stoessl AJ, Young GB, Feasby TE (1985) "Intracerebral haemorrhage and angiographic beading following ingestion of catecholaminergics." Stroke, 16, p. 734-6
  12. Covington TR, eds., Lawson LC, Young LL (1993) "Handbook of Nonprescription Drugs." Washington, DC: American Pharmaceutical Association
  13. (2001) "Product Information. Sudafed (pseudoephedrine)." Glaxo Wellcome
  14. Kizer KW (1984) "Intracranial hemorrhage associated with overdose of decongestant containing phenylpropanolamine" Am J Emerg Med, 2, p. 180-1
  15. Edwards M, Russo L, Harwood-Nuss A (1987) "Cerebral infarction with a single oral dose of phenylpropanolamine." Am J Emerg Med, 5, p. 163-4
  16. Lake CR, Gallant S, Masson E, Miller P (1990) "Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports." Am J Med, 89, p. 195-208
  17. Lake CR, Zaloga G, Bray J, Rosenberg D, Chernow B (1989) "Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study." Am J Med, 86, p. 427-32
  18. Lake CR, Zaloga G, Clymer R, Quirk RM, Chernow B (1988) "A double dose of phenylpropanolamine causes transient hypertension." Am J Med, 85, p. 339-43
  19. Bernstein E, Diskant BM (1982) "Phenylpropanolamine: a potentially hazardous drug." Ann Emerg Med, 11, p. 311-5
  20. Kroenke K, Omori DM, Simmons JO, Wood DR, Meier NJ (1989) "The safety of phenylpropanolamine in patients with stable hypertension." Ann Intern Med, 111, p. 1043-4
  21. Pentel PR, Mikell FL, Zavoral JH (1982) "Myocardial injury after phenylpropanolamine ingestion." Br Heart J, 47, p. 51-4
  22. Howrie DL, Wolfson JH (1983) "Phenylpropanolamine-induced hypertensive seizures." J Pediatr, 102, p. 143-5
  23. Horowitz JD, Lang WJ, Howes LG, Fennessy MR, Christophidis N, Rand MJ, Louis WJ (1980) "Hypertensive responses induced by phenylpropanolamine in anorectic and decongestant preparations." Lancet, 1, p. 60-1
  24. Johnson DA, Etter HS, Reeves DM (1983) "Stroke and phenylpropanolamine use" Lancet, 2, p. 970
  25. McEwen J (1983) "Phenylpropanolamine-associated hypertension after the use of "over- the-counter" appetite-suppressant products." Med J Aust, 2, p. 71-3
  26. Elliott CF, Whyte JC (1981) "Phenylpropanolamine and hypertension." Med J Aust, 1, p. 715
  27. Maher LM, Peterson PL, Dela-Cruz C (1987) "Postpartum intracranial hemorrhage and phenylpropanolamine use" Neurology, 37, p. 1686
  28. Kase CS, Foster TE, Reed JE, Spatz EL, Girgis GN (1987) "Intracerebral hemorrhage and phenylpropanolamine use." Neurology, 37, p. 399-404
  29. Kikta DG, Devereaux MW, Chandar K (1985) "Intracranial hemorrhages due to phenylpropanolamine." Stroke, 16, p. 510-2
  30. Clark JE, Simon WA (1983) "Cardiac arrhythmias after phenylpropanolamine ingestion." Drug Intell Clin Pharm, 17, p. 737-8
  31. Noble R (1988) "A controlled clinical trial of the cardiovascular and psychological effects of phenylpropanolamine and caffeine." Drug Intell Clin Pharm, 22, p. 296-9
  32. O'Connell MB, Gross CR (1991) "The effect of multiple doses of phenylpropanolamine on the blood pressure of patients whose hypertension was controlled with beta blockers." Pharmacotherapy, 11, p. 376-81
  33. O'Connell MB, Gross CR (1990) "The effect of single-dose phenylpropanolamine on blood pressure in patients with hypertension controlled by beta blockers." Pharmacotherapy, 10, p. 85-91
  34. Chin C, Choy M (1993) "Cardiomyopathy induced by phenylpropanolamine." J Pediatr, 123, p. 825-7
  35. American Medical Association, Division of Drugs and Toxicology (1994) "Drug evaluations annual 1994." Chicago, IL: American Medical Association;
  36. Lee KY, Beilin LJ, Vandongen R (1979) "Severe hypertension after ingestion of an appetite suppressant (phenylpropanolamine) with indomethacin." Lancet, 1, p. 1110-1
  37. Gibson GJ, Warrell DA (1972) "Hypertensive crises and phenylpropanolamine." Lancet, 2, p. 492-3
  38. Frewin DB (1983) "Phenylpropanolamine. How safe is it?" Med J Aust, 2, p. 54-5
  39. Lee KY, Beilin LJ, Vandongen R (1979) "Severe hypertension after administration of phenylpropanolamine" Med J Aust, 1, p. 525-6
  40. Horowitz JD, McNeil JJ, Sweet B, Mendelsohn FA, Louis WJ (1979) "Hypertension and postural hypotension induced by phenylpropanolamine (Trimolets)." Med J Aust, 1, p. 175-6
  41. Frewin DB, Leonello PP, Frewin ME (1978) "Hypertension after ingestion of Trimolets." Med J Aust, 2, p. 497-8
  42. Teh AY (1979) "Phenylpropanolamine and hypertension" Med J Aust, 2, p. 425-6
  43. Shapiro SR (1969) "Hypertension due to anorectic agent." N Engl J Med, 280, p. 1363
  44. Maher LM, Peterson PL, Dela-Cruz C (1987) "Postpartum intracranial hemorrhage and phenylpropanolamine use." Neurology, 37, 1886,1890
  45. Fallis RJ, Fisher M (1985) "Cerebral vasculitis and hemorrhage associated with phenylpropanolamine." Neurology, 35, p. 405-7
  46. Caperton E (1983) "Raynaud's phenomenon. Role of diet pills and cold remedies." Postgrad Med, 73, p. 291-2
  47. McDowell JR, LeBlanc HJ (1985) "Phenylpropanolamine and cerebral hemorrhage." West J Med, 142, p. 688-91
  48. Williams DM (1990) "Phenylpropanolamine hydrochloride" Am Pharm, NS30, p. 47-50
  49. Dowse R, Scherzinger SS, Kanfer I (1990) "Serum concentrations of phenylpropanolamine and associated effects on blood pressure in normotensive subjects: a pilot-study." Int J Clin Pharmacol Ther Toxicol, 28, p. 205-10
  50. Pentel PR, Aaron C, Paya C (1985) "Therapeutic doses of phenylpropanolamine increase supine systolic blood pressure." Int J Obes, 9, p. 115-9
  51. Finton CK, Barton M, Chernow B (1982) "Possible adverse effects of phenylpropanolamine (diet pills) on sympathetic nervous system function--caveat emptor!" Mil Med, 147, p. 1072
  52. (2022) "Product Information. Adrenalin (EPINEPHrine)." Apothecon Inc
  53. Leo PJ, Hollander JE, Shih RD, Marcus SM (1996) "Phenylpropanolamine and associated myocardial injury." Ann Emerg Med, 28, p. 359-62
  54. Gill ND, Shield A, Blazevich AJ, Zhou S, Weatherby RP (2000) "Muscular and cardiorespiratory effects of pseudoephedrine in human athletes." Br J Clin Pharmacol, 50, p. 205-13
  55. Haller CA, Benowitz NL (2000) "Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids." N Engl J Med, 343, p. 1833-8
  56. Mansoor GA (2001) "Herbs and alternative therapies in the hypertension clinic." Am J Hypertens, 14(9 Pt 1), p. 971-5
  57. Samenuk D, Link MS, Homoud MK, et al. (2002) "Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine." Mayo Clin Proc, 77, p. 12-6
  58. (2016) "Product Information. Akovaz (ephedrine)." Eclat Pharmaceuticals
View all 58 references
Major

Sympathomimetics (applies to Xylocaine with Epinephrine Dental Cartridges) dehydration

Major Potential Hazard, High plausibility.

The use of sympathomimetic amines has been infrequently associated with significant hypotension especially in dehydrated patients secondary to the drug's beta-2 mediated vasodilation. Hypovolemia should be corrected, if possible, before administering sympathomimetic amines. Blood pressure and ECG should be monitored at regular intervals. Monitoring of cardiac output and pulmonary wedge pressure may also be desired.

References

  1. (2001) "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals
  2. (2022) "Product Information. Epifrin (EPINEPHrine ophthalmic)." Allergan Inc
  3. (2022) "Product Information. Adrenalin (EPINEPHrine)." Apothecon Inc
  4. (2001) "Product Information. Levophed Bitartrate (norepinephrine)." Sanofi Winthrop Pharmaceuticals
View all 4 references
Moderate

Antiarrhythmics (applies to Xylocaine with Epinephrine Dental Cartridges) electrolyte imbalance

Moderate Potential Hazard, High plausibility. Applicable conditions: Hypokalemia, Hyperkalemia, Magnesium Imbalance

Electrolyte imbalance can alter the therapeutic effectiveness of antiarrhythmic agents. Hypokalemia and hypomagnesemia can reduce the effectiveness of antiarrhythmic agents. In some cases, these disorders can exaggerate the degree of QTc prolongation and increase the potential for torsade de pointes. Hyperkalemia can potentiate the toxic effects of antiarrhythmic agents. Electrolyte imbalance should be corrected prior to initiating antiarrhythmic therapy. Clinical monitoring of cardiac function and electrolyte concentrations is recommended.

References

  1. (2002) "Product Information. Tonocard (tocainide)." Merck & Co., Inc
  2. (2002) "Product Information. Ethmozine (moricizine)." DuPont Pharmaceuticals
  3. (2002) "Product Information. Cordarone (amiodarone)." Wyeth-Ayerst Laboratories
  4. (2002) "Product Information. Xylocaine (lidocaine)." Astra-Zeneca Pharmaceuticals
  5. (2001) "Product Information. Procan SR (procainamide)." Parke-Davis
  6. (2001) "Product Information. Pronestyl (procainamide)." Apothecon Inc
  7. "Product Information. Quinidex Extentabs (quiNIDine)." Wyeth-Ayerst Laboratories
  8. (2001) "Product Information. Tambocor (flecainide)." 3M Pharmaceuticals
  9. (2001) "Product Information. Mexitil (mexiletine)." Boehringer-Ingelheim
  10. "Product Information. Rythmol (propafenone)." Knoll Pharmaceutical Company
  11. (2001) "Product Information. Norpace (disopyramide)." Searle
  12. (2022) "Product Information. Cordarone (amiodarone)." Apothecon Inc
  13. (2001) "Product Information. Corvert (ibutilide)." Pharmacia and Upjohn
View all 13 references
Moderate

Epinephrine (applies to Xylocaine with Epinephrine Dental Cartridges) parkinson's disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Parkinsonism, Neurologic Disorder

Epinephrine should be administered with caution to patients with Parkinson's disease as these patients may experience psychomotor agitation or notice a temporary worsening of symptoms.

References

  1. (2022) "Product Information. Adrenalin (EPINEPHrine)." Apothecon Inc
Moderate

Sympathomimetics (applies to Xylocaine with Epinephrine Dental Cartridges) acidosis

Moderate Potential Hazard, High plausibility.

Acidosis, hypoxia, and hypercapnia may reduce the effectiveness of sympathomimetic amines in raising blood pressure. These conditions should be corrected before initiating therapy with sympathomimetic amines, if possible. Monitoring the patients acid-base balance, carbon dioxide levels, and oxygen saturation is recommended.

References

  1. (2001) "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals
  2. (2022) "Product Information. Epifrin (EPINEPHrine ophthalmic)." Allergan Inc
  3. (2022) "Product Information. Adrenalin (EPINEPHrine)." Apothecon Inc
  4. (2001) "Product Information. Levophed Bitartrate (norepinephrine)." Sanofi Winthrop Pharmaceuticals
View all 4 references
Moderate

Sympathomimetics (applies to Xylocaine with Epinephrine Dental Cartridges) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus

Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.

References

  1. Covington TR, eds., Lawson LC, Young LL (1993) "Handbook of Nonprescription Drugs." Washington, DC: American Pharmaceutical Association
  2. (2001) "Product Information. Sudafed (pseudoephedrine)." Glaxo Wellcome
  3. American Medical Association, Division of Drugs and Toxicology (1994) "Drug evaluations annual 1994." Chicago, IL: American Medical Association;
  4. Williams DM (1990) "Phenylpropanolamine hydrochloride" Am Pharm, NS30, p. 47-50
  5. (2022) "Product Information. Adrenalin (EPINEPHrine)." Apothecon Inc
  6. (2016) "Product Information. Akovaz (ephedrine)." Eclat Pharmaceuticals
View all 6 references

Xylocaine with Epinephrine Dental Cartridges drug interactions

There are 694 drug interactions with Xylocaine with Epinephrine Dental Cartridges (epinephrine / lidocaine).

Xylocaine with Epinephrine Dental Cartridges alcohol/food interactions

There are 2 alcohol/food interactions with Xylocaine with Epinephrine Dental Cartridges (epinephrine / lidocaine).


Report options

Loading...
QR code containing a link to this page

More about Xylocaine with Epinephrine Dental Cartridges (epinephrine / lidocaine)

Related treatment guides

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.